Bausch + Lomb Corporation (BLCO.TO) TSX

20.09

+0.02(+0.10%)

Updated at August 18 02:05PM

Currency In CAD

Bausch + Lomb Corporation

Address

520 Applewood Crescent

Vaughan, ON L4K 4B4

Canada

Phone

905 695 7700

Sector

Healthcare

Industry

Medical - Instruments & Supplies

Employees

13500

First IPO Date

May 06, 2022

Key Executives

NameTitlePayYear Born
Mr. Brenton L. Saunders J.D.Chief Executive Officer & Chairman6.92M1970
Mr. Andrew J. StewartPresident of Global Pharmaceuticals & International Consumer1.67M1976
Dr. Yehia Hashad M.D., Ph.D.Executive Vice President of Research & Development and Chief Medical officer1.88M1968
Mr. A. Robert D. BaileyExecutive Vice President & Chief Legal Officer2.05M1963
Mr. Osama A. EldessoukyExecutive Vice President & Chief Financial Officer2.25M1972
Mr. Alan Waterhouse CPFA, MBAExecutive Vice President and Chief Supply Chain & Operations Officer01960
Mr. Jonathon L. KellermanChief Compliance Officer0N/A
Mr. T.J. CrawfordChief Communications Officer0N/A
Dr. Manisha A. Narasimhan Ph.D.Chief Corporate Development & Digital Officer01977
Mr. Frederick J. MunschSenior Vice President, Controller & Chief Accounting Officer01971

Description

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.